Hospital Acquired Pneumonia Drugs Market to Be Dominated by Biological Drugs, Phase Iii Drugs to Garner Us$3.8 Billion

Hospital acquired infections can create several complications for patients. These infections, caused due to multidrug resistant organisms, drastically reduce the convalescence of a patient and is often accompanied with comorbidities.

Conventional antibiotics fail to curb such infections, since these organisms are multidrug resistant. Pneumonia is one of the most common infections caused due to prolonged stays in hospital premises. Instances of hospital acquired infections are most common among patients with weak immunity, such as elderly and infant patients. Post-surgical infections and infections caused due to enteral feeding constitute the common cases of hospital acquired diseases. High prevalence of hospital acquired pneumonia is likely to boost the pipeline for hospital acquired pneumonia therapeutics.

To study the prospects of the pipeline for global hospital acquired pneumonia drugs Market, Transparency Market Research has released a report titled “Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”. The report states that the six drugs currently in phase III of testing are likely to generate total revenue of US$3.8 billion by the end of 2020.

Browse the full Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Report at

The report has identified that the stage III of pipeline analysis currently has five investigational drugs and one vaccine. Ten other candidates have successfully entered the early stages of pipeline analysis. Drugs that have reached phase III of clinical trials include AstraZeneca PLC’s Ceftazidime/avibactam, Achaogen, Inc’s Plazomicin, GlaxoSmithKline’s Synflorix, Ceftolozane/tazobactam, Bayer Healthcare’s Amikacin inhale, and Tedizolid phosphate by Cubist Pharmaceuticals. If approved, these drugs could be available in the market by 2017. The...